NICE Denies Coverage for J&J's Imbruvia for Rare Cancer

Oct 17, 2016

In a draft guidance, UK's National Institute of Health and Care Excellence (NICE) denied coverage for Johnson & Johnson's Imbruvica for treating Waldenstrom’s macroglobulinaemia.

Waldenstrom’s macroglobulinaemia is a rare and incurable cancer of the lymphatic system -- a form of non-Hodgkin's lymphoma.

While NICE acknowledged the unmet need for treating patients with this disease, the agency said there is no cost-effectiveness evidence for the group and that NICE could not back the drug on the level of data provided.

The guidance, however, is not final and could change after the appraisal committee meets to consider further comments.

Read the guidance

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments